Arbutus Biopharma Cp (ABUS) Stock Price, Quote & News

Company Profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the poten...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 469 0914

Website: www.arbutusbio.com

Address:

701 Veterans Circle, Warminster, United States

SKCSS Jul. 16 at 9:53 PM

$ABUS Let's look at the positives shall we? We've spent the last year above $3 aside from one day. Remember the times when we it was a chore to even reach 3.

0 · Reply

Nile1 Jul. 16 at 8:00 PM

$ABUS finally added

1 · Reply

Grtgooglymoogly Jul. 16 at 7:55 PM

$ABUS Hope Whitefort and all are happy with the changes they pushed for. Maybe another public letter is in order to say if they're happy or not.....

1 · Reply

jakejill87 Jul. 16 at 7:47 PM

$ABUS 7000 shares now. Come on give us a 30$ per share buyout at least

0 · Reply

Nile1 Jul. 16 at 4:07 PM

$ABUS as soon as I placed my bid at $3.11 they start moving it up !

1 · Reply

Planetpaprika Jul. 16 at 3:41 PM

$ABUS Never seen this site... A complete litigation chronology ! https://www.courtlistener.com/docket/67142175/arbutus-pharma-corp-v-pfizer-inc/

2 · Reply

MyBrokenBus Jul. 16 at 2:54 PM

$ABUS half a day's trading volume in the first hour and... 0% movement? pretty wild

1 · Reply

RL123 Jul. 16 at 2:51 PM

$BRNS hwg $ABUS next

1 · Reply

LASTOCKS19 Jul. 16 at 8:07 AM

$ABUS Arbutus Biopharma is being included (again) in the Solactive U.S. Biotechnology Index, effective Aug 7, 2025. What that means. More passive fund buying Increased visibility in biotech Potential short-term price boost and longterm

0 · Reply

Grtgooglymoogly Jul. 15 at 3:58 PM

$ABUS Does anyone know or have an educated guess when the next AB-101 clinical data might be revealed? End of year?

3 · Reply

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

May 14, 2025, 7:30 AM EDT - 2 months ago

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 7, 2025, 2:01 AM EDT - 2 months ago

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Apr 23, 2025, 2:01 AM EDT - 3 months ago

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Mar 27, 2025, 7:56 AM EDT - 3 months ago

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Mar 27, 2025, 7:30 AM EDT - 3 months ago

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Mar 3, 2025, 9:15 AM EST - 4 months ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ROIV

Feb 25, 2025, 7:00 AM EST - 5 months ago

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Jan 30, 2025, 3:40 PM EST - 5 months ago

Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.

BUR CDZI

Jan 13, 2025, 7:30 AM EST - 6 months ago

Arbutus Provides 2025 Corporate and Financial Update

Jan 7, 2025, 7:56 AM EST - 6 months ago

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development

Dec 3, 2024, 8:00 AM EST - 8 months ago

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Nov 26, 2024, 7:30 AM EST - 8 months ago

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Nov 15, 2024, 11:02 AM EST - 8 months ago

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Nov 14, 2024, 7:30 AM EST - 8 months ago

Arbutus to Present at Jefferies London Healthcare Conference

Nov 6, 2024, 2:52 PM EST - 9 months ago

Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript

Oct 23, 2024, 7:30 AM EDT - 9 months ago

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Oct 15, 2024, 8:16 AM EDT - 9 months ago

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Sep 3, 2024, 7:30 AM EDT - 11 months ago

Arbutus to Participate in Two Upcoming Investor Conferences

Aug 1, 2024, 2:00 PM EDT - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 18, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Jul 5, 2024, 5:29 AM EDT - 1 year ago

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Jun 6, 2024, 11:15 AM EDT - 1 year ago

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Jun 5, 2024, 2:30 AM EDT - 1 year ago

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Jun 3, 2024, 9:50 AM EDT - 1 year ago

Arbutus Distributors Ltd. News Release

May 29, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Participate in Jefferies Global Healthcare Conference

May 22, 2024, 2:00 AM EDT - 1 year ago

Arbutus to Present Imdusiran Data at EASL Congress 2024

May 17, 2024, 9:00 AM EDT - 1 year ago

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

May 2, 2024, 1:15 PM EDT - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript

May 2, 2024, 7:30 AM EDT - 1 year ago

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 7:25 AM EDT - 1 year ago

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

Apr 18, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Apr 4, 2024, 8:30 AM EDT - 1 year ago

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Feb 29, 2024, 1:05 PM EST - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 7:30 AM EST - 1 year ago

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Feb 15, 2024, 7:30 AM EST - 1 year ago

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Jan 8, 2024, 7:30 AM EST - 1 year ago

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Nov 9, 2023, 4:01 PM EST - 1 year ago

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Nov 7, 2023, 11:06 AM EST - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 7:30 AM EST - 1 year ago

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 7:15 AM EST - 1 year ago

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Oct 24, 2023, 7:30 AM EDT - 1 year ago

Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Oct 18, 2023, 7:30 AM EDT - 1 year ago

Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference

Oct 11, 2023, 8:05 AM EDT - 1 year ago

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023

Sep 11, 2023, 4:15 PM EDT - 2 years ago

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

Jul 20, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update

Jul 12, 2023, 7:30 AM EDT - 2 years ago

Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors

Jul 10, 2023, 4:01 PM EDT - 2 years ago

Arbutus Appoints Two New Executives

SKCSS Jul. 16 at 9:53 PM

$ABUS Let's look at the positives shall we? We've spent the last year above $3 aside from one day. Remember the times when we it was a chore to even reach 3.

0 · Reply

Nile1 Jul. 16 at 8:00 PM

$ABUS finally added

1 · Reply

Grtgooglymoogly Jul. 16 at 7:55 PM

$ABUS Hope Whitefort and all are happy with the changes they pushed for. Maybe another public letter is in order to say if they're happy or not.....

1 · Reply

jakejill87 Jul. 16 at 7:47 PM

$ABUS 7000 shares now. Come on give us a 30$ per share buyout at least

0 · Reply

Nile1 Jul. 16 at 4:07 PM

$ABUS as soon as I placed my bid at $3.11 they start moving it up !

1 · Reply

Planetpaprika Jul. 16 at 3:41 PM

$ABUS Never seen this site... A complete litigation chronology ! https://www.courtlistener.com/docket/67142175/arbutus-pharma-corp-v-pfizer-inc/

2 · Reply

MyBrokenBus Jul. 16 at 2:54 PM

$ABUS half a day's trading volume in the first hour and... 0% movement? pretty wild

1 · Reply

RL123 Jul. 16 at 2:51 PM

$BRNS hwg $ABUS next

1 · Reply

LASTOCKS19 Jul. 16 at 8:07 AM

0 · Reply

Grtgooglymoogly Jul. 15 at 3:58 PM

$ABUS Does anyone know or have an educated guess when the next AB-101 clinical data might be revealed? End of year?

3 · Reply

StockosaurusTex Jul. 15 at 11:35 AM

$ABUS

0 · Reply

SKCSS Jul. 14 at 10:06 PM

$ABUS It's as quiet in here as I've ever seen it.

3 · Reply

Grtgooglymoogly Jul. 14 at 8:01 PM

$ABUS Is that a pulse?

1 · Reply

Stocks_pumpr Jul. 14 at 8:00 PM

$ABUS

0 · Reply

Hjm57 Jul. 11 at 11:26 PM

$ABUS Any answers on why Judge Goldberg has been replaced?

2 · Reply

jakejill87 Jul. 11 at 7:50 PM

$ABUS Trump was a fan of this judge, and he even voted for him and not only that we know how Trump and Republicans feel about all the Covid and vaccine stuff anyway... I have a feeling I know how this might go. Now that Goldberg isn’t protecting Moderna and in doing so being forced to protect Pfizer, I think that this really begins to speed up finally.

3 · Reply

Nile1 Jul. 11 at 7:22 PM

$ABUS if nobody is selling why it dropped ? I tried to add on the bid side today but never filled my order

1 · Reply

NakdEnergy Jul. 11 at 6:12 PM

$ABUS this is a great board with excellent DD and relevant input that’s objectively positive based on the facts. That being said, who the hell is selling this to keep the price down?

1 · Reply

RL123 Jul. 11 at 5:34 PM

$ABUS just do an $INKT and I’ll be happy

1 · Reply

TruthTooPower Jul. 11 at 4:19 PM

$ABUS !!! What is PT When They Resolve The Court Case? $25.00

2 · Reply

GABIRODZ01 Jul. 11 at 3:55 PM

$ABUS Goodbye Judge Goldberg?

2 · Reply

Thepatientone Jul. 11 at 3:05 PM

$ABUS - 3

0 · Reply

Market Cap	592.57M
Revenue (ttm)	18.14M
Net Income (ttm)	-72.85M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	649,900
Avg Vol	936,122
Day's Range	N/A - N/A
Shares Out	188.72M
Stochastic %K	2%
Beta	1.98
Analysts	Strong Sell
Price Target	$4.50